Day 1

Introductory remarks

Mike Allen, Regional Medical Advisor (Antibiotics), MSD UK & BSAC General Secretary

Session 1 – Keynote presentation

  • Global Challenges and Goals for AMR – Reflections from the UNGA High Level Meeting
    • Ana Cristina Gales, Federal University of São Paulo, Brazil

Session 2 – Drug discovery: new targets and new chemistry

Chair: Alan Hennessy, Discovery and Exploratory Research Team Leader, GARDP

  • Antibiotic class with potent in vivo activity targeting lipopolysaccharide synthesis in Gram-negative bacteria
    • Douglas Huseby, Uppsala University
  • The Ersilia Model Hub: Open Source AI for Antimicrobial Drug Discovery
    • Miquel Duran-Frigola, Ersilia Open Source Initiative
  • Immunotherapy focused on infectious diseases

Session 3 – Preclinical antimicrobial development

Chair: François Franceschi, Head of Asset Evaluation and Development and Serious Bacterial Infections Project Leader, GARDP

  • FabI inhibitor for Neisseria gonorrhoeae (Debio1453)
    • David Cameron, Debiopharm
  • EBL-1463, a non-beta-lactam PBP inhibitor impervious to beta-lactamase hydrolysis for the treatment of CRE infections
    • François Moreau, Tamrisa Innovation
  • An Immune Approach for the Treatment of Sepsis
    • Jessica Field, Cellics Therapeutics

Session 4 – Panel discussion 

Chair: Susana Frasés Carvajal, Federal University of Rio de Janeiro

  • The antifungal development pipeline
    • Maurizio Del Poeta, Stony Brook University
    • Leah Cowen, University of Toronto

Day one closing remarks

Christopher Longshaw, Shionogi BV & BSAC Honorary Treasurer

Day 2

Introductory remarks

Christopher Longshaw, Shionogi BV & BSAC Honorary Treasurer

Session 5 – Clinical Development and Use of New agents

Chair: Mike Allen, Regional Medical Advisor (Antibiotics), MSD UK & BSAC General Secretary

  • Development pathways in antibiotic development – This presentation has been developed by Pfizer Inc
    • Halley Rogers, Pfizer Inc
  • The challenges and opportunities in the preclinical development of cefepime-enmetazobactam
    • Maneesh Paul, Microvioma
  • The challenges and opportunities of the development pathway for Phage therapy
    • Ariel Cohen, BiomX/Adaptive Phage Therapeutics

Session 6 – Oral Poster Presentations

Chair: Tom Ashfield, Health Strategist & BSAC Council

  • Leveraging stem cell technology to identify new treatment options for nontuberculous mycobacteria
    • Sohinee Sarkar, Murdoch Children’s Research Institute
  • Utilising actinobacteria diversity in the Great Salt Plains to look for novel TB therapeutics
    • Amanda Jones, Northumbria University
  • Building an on-panel enzyme detection system to reveal and resolve clinically problematic beta-lactamases in Gram negative bacteria
    • Nicole Jackson, BioAmp Diagnostics
  • Functional high-throughput screening identifies microRNAs regulating infection by Staphylococcus aureus
    • Caio Haddad Franco, AccelBio Collaborative Laboratory, University of Coimbra
  • Computational study to identify novel Metallo-β-lactamases inhibitors using virtual screening, molecular docking, dynamic simulations, and ADMET prediction
    • Fatima Mourabiti, University of Casablanca

Session 7 – Control of infectious diseases with biotherapeutics and beyond

Chair: Fausto Almeida, University of São Paulo

  • The role of vaccines to tackle AMR
    • Angela Brueggemann, University of Oxford
  • Therapeutic antibodies and infectious diseases
    • Liise-anne Pirofski, Albert Einstein College of Medicine and Montefiore Medical Center
  • Jumbo Bacteriophages for IPC
    • Gregorio Iraola, Kinzbio

Session 8 – Panel discussion: Acceleration of development/access of POCTs for STI management

Chair: Teri Roberts, Public Health Senior Manager, GARDP

  • Moving from syndromic to aetiological approaches for STI management: a focus on implementation challenges and opportunities in LMIC settings
    • Chido Dziva Chikwari, London School of Hygiene & Tropical Medicine
  • Developing a low cost N. gonorrhoeae lateral flow assay: challenges and opportunities
    • Cecilia Ferreyra, FINDcec
  • Developer’s experience of developing a test for N. gonorrhoeae and guidance for POCT developers on ceftriaxone-resistant N. gonorrhoeae targets
    • Alex Trick, Prompt Diagnostics
  • Clinical use and uptake of STI POCTs in LMICs
    • Yukari Manabe, Johns Hopkins Center for Innovative Diagnostics for Infectious Diseases
  • Panel discussion and Q&A

Closing remarks

Alison Luckey, GARDP

This year, for the first time, we are providing quality-controlled transcription and translation into Spanish and Portuguese on all recordings. We hope you find this useful. Please let us know what you think about the subtitles and translations in this short survey. It will help us understand if they are useful for you for future conferences or webinars.